Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
January 04, 2024 06:30 ET
|
Kynexis
KYN-5356 is an innovative, first-in-class small molecule that targets KAT-II, a key enzyme in the kynurenine pathwayTopline results are expected in the second half of 2024 NAARDEN, The Netherlands,...
Kynexis Launched to Advance Precision Therapeutics for Brain Diseases
November 07, 2023 05:00 ET
|
Kynexis
- Lead Candidate KYN-5356, a First-In-Class Small Molecule KAT-II Inhibitor, Advancing Toward the Clinic for Cognitive Impairment Associated With Schizophrenia - €57 Million Series A Led by Forbion ...